drugset / Trial / NCT02159469

Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism

NCT02159469

Phase 3 Completed 150 enrolled Antares Pharma Inc.
NaSingle-groupOpen-labelTreatment

Summary

Evaluation of efficacy and safety of testosterone enanthate administered subcutaneously using an auto-injector

Timeline

Start
2014-07
Primary completion
2015-02
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Enanthate Small molecule 50 mg Subcutaneous
Subject Testosterone Enanthate Small molecule 75 mg Subcutaneous
Subject Testosterone Enanthate Small molecule 100 mg Subcutaneous

Indications